吉非替尼与多西紫杉醇二线治疗非小细胞肺癌的疗效比较

Comparison of gefitinib and docetaxel in the treatment of advanced non small cell lung cancer patients who have failed to previous chemotherapy

目的探讨吉非替尼与多西紫杉醇单药作为二线治疗对晚期非小细胞肺癌的疗效和不良反应。方法将既往一线化疗失败的51例晚期非小细胞肺癌患者,分为吉非替尼组和国产多西紫杉醇组进行治疗观察。结果吉非替尼组临床获益率为53.8%,一年生存率为34.6%;国产多西紫杉醇组临床获益率为48%,一年生存率为28%。两组临床获益比较差异无显著性(P>0.05),但吉非替尼组血液毒副反应明显小于多西紫杉醇组,生活质量评分改善率更高(P<0.05)。结论对化疗失败的晚期非小细胞肺癌,吉非替尼单药疗效与多西紫杉醇单药疗效相近,但不良反应更轻,对生活质量改善率更高。

Objective To evaluate the antitumor efficacy and toxicity of Docetaxel and Gefitinib, selective epidermal growth factor receptor tyrosine kinase inhibitor,in the treatment of advanced non small cell lung cancer patients who had failed to previous chemotherapy. Methods Fifty one patients with ad- vanced NSCLC who were previously treated with chemotherapy were enrolled in Gefitinib group and Docetaxel group. Results In Gefitinib group disease control rate was 53.8% and 1 year survival rate was 34.6% , which showed no differences with in Docetaxel group （48% and 28% , respectively）. However, the hematologic toxicity of Gefitinib group was significantly lower than that of Docetaxel group and the improvement rate of quality of life was higher in patients who received Gefitinib treatment. Conclusion Gefitinib has a similar effect of antitumor activity with Docetaxel in advanced NSCLC patients who have failed in previous chemotherapy. The toxicity was lower and the improvement rate of quality of life was higher in Gefitinib group.